Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Spain,Denmark,United Kingdom,Greece,France,Czech Republic,Germany,Italy,Sweden,Poland
Trial Manager
MAJ Il y a 5 ans
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.
Pays
Argentina
,
Australia
,
Austria
,
Belgium
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Korea, Republic of
,
Mexico
,
Netherlands
,
Poland
,
Portugal
,
Saudi Arabia
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Taiwan, Province of China
,
Turkey
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
This study will assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. The aim of the study is to confirm the rates of complete molecular remission (CMR) of nilotinib in newly diagnosed CML chronic phase patients in a pan-European population using the EUTOS standardized laboratories.
Pays
Austria
,
Belgium
,
Bulgaria
,
Croatia
,
Czech Republic
,
Denmark
,
Estonia
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Latvia
,
Lithuania
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Romania
,
Slovakia
,
Slovenia
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Study Objectives: To collect and describe demographics, disease-management, and treatment outcomes of Myelodysplastic Syndromes (MDS) patients who are newly diagnosed and classified according to the WHO criteria. To perform observational studies concerning relevant scientific research questions in MDS using clinical data and biological samples, and to present relevant research outcomes in the fields of diagnosis and prognostication, health related quality of life issues, health economics, and risk stratification for newly developed classes of drugs. To disseminate results of the studies to all stakeholders involved.
Pays
Austria
,
Croatia
,
Czech Republic
,
Denmark
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Portugal
,
Romania
,
Serbia
,
Spain
,
Sweden
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai ouvert aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
Pays
Australia
,
China
,
Colombia
,
Czech Republic
,
Denmark
,
France
,
Germany
,
Greece
,
Ireland
,
Israel
,
Italy
,
Korea, Republic of
,
Malaysia
,
Mexico
,
Poland
,
Slovakia
,
Spain
,
Sweden
,
Switzerland
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
Trial Manager
MAJ Il y a 5 ans
Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis
To compare the therapeutic and radiographic effects and safety between etanercept, methotrexate, and the etanercept/methotrexate combination in patients with rheumatoid arthritis.
Pays
Australia
,
Austria
,
Belgium
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Romania
,
Spain
,
Sweden
,
United Kingdom
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1